Clinical Trial Detail

NCT ID NCT02367040
Title Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Bayer
Indications

marginal zone B-cell lymphoma

non-Hodgkin lymphoma

lymphoplasmacytic lymphoma

follicular lymphoma

Therapies

Rituximab

Copanlisib

Age Groups: adult

No variant requirements are available.